Growth factors in corneal transplant surgery
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests whether adding a special growth factor solution to the fluid used during corneal transplant surgery helps the transplant heal better. It is for patients undergoing a specific type of corneal transplant called DSEK or DMEK.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having a DSEK or DMEK corneal transplant at Bascom Palmer Eye Institute or Price Vision Group.
- The donor cornea has been preserved for less than 14 days.
- Your vision in the other eye is 20/40 or better (can read the big 'E' on the eye chart).
- You have not had a previous corneal transplant in the same eye.
- You have not had any eye surgeries other than cataract surgery (for example, no glaucoma drainage tubes or silicone oil).
- You are not taking medications that suppress your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares outcomes from two cornea transplant procedures in people with FECD, a disease that makes the cornea swell and affect vision. It may help you and others by identifying which approach best supports clear vision and stable corneal thickness after surgery.
This trial tests a new corneal implant to treat corneal swelling caused by Fuchs' dystrophy or after cataract surgery. It aims to improve vision and reduce the need for a full corneal transplant.
This trial looks at how to manage medicine around DMEK corneal transplant surgery to improve eye outcomes and safety. It may help people having this specific type of cornea transplant by testing an approach in the time after surgery.
This Phase 1 trial tests a new, lab-made tissue transplant to improve corneal clarity in people with certain types of corneal endothelium failure (eye swelling) caused by specific conditions. The main goal is to check safety and see if vision and corneal health improve.
This trial tests an investigational cell therapy called EO2002 for people with corneal edema (swelling of the clear front part of the eye) caused by endothelial dysfunction, which can happen with Fuchs dystrophy or after cataract surgery. The treatment aims to restore the inner layer of the cornea to reduce swelling and improve vision.
This trial tests a type of corneal transplant (DMEK) in people who have had previous eye surgeries, such as vitrectomy or glaucoma surgery. It aims to see if the transplant works well even in these complicated cases.
Hear when a new Fuchs' Endothelial Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.